WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1891-01-01
- Employees
- 10K
- Market Cap
- -
FDA-Approved Alzheimer's Drug Lecanemab Shows Manageable Safety Profile in Real-World Setting
• WashU Medicine researchers found only 1% of Alzheimer's patients treated with lecanemab experienced severe side effects requiring hospitalization, confirming clinical trial safety data in a real-world setting.
• Patients with very mild Alzheimer's symptoms showed significantly lower risk (1.8%) of adverse events compared to those with mild symptoms (27%), suggesting earlier treatment may optimize both efficacy and safety.
• The study of 234 patients demonstrates that specialized memory clinics can effectively manage ARIA (amyloid-related imaging abnormalities), with most cases being asymptomatic and resolving without intervention.
Heavy Cannabis Use Linked to Triple Mortality Risk and Rising Psychosis Cases, Studies Find
• People diagnosed with cannabis use disorder (CUD) face nearly triple the risk of death over five years compared to the general population, with a tenfold increase in suicide risk, according to a large Canadian study.
• Since Canada's 2018 cannabis legalization, cases of psychosis and schizophrenia linked to CUD have significantly increased, with young adults aged 19-24 most vulnerable to these effects.
• Medical marijuana users show equal or higher addiction rates than recreational users, with researchers finding no evidence that medical cannabis carries reduced addiction risk.
AI Advances in Breast Cancer Detection: New Technologies Show Promise for Earlier Diagnosis
• AI technology developed at Washington University can analyze sequential mammograms to identify subtle tissue changes, predicting breast cancer risk 2.3 times more accurately than standard methods.
• Scottish researchers have combined AI with laser spectroscopy analysis of blood samples, achieving 98% effectiveness in detecting stage 1a breast cancers and 90% accuracy in differentiating between cancer subtypes.
• These AI-powered diagnostic approaches could significantly improve early detection rates, potentially increasing treatment success and survival outcomes for breast cancer patients.
Orca Bio's Phase III Precision-T Study Shows Promise for Novel T-Cell Immunotherapy in Blood Cancers
• Orca Bio announced positive results from its pivotal Phase III Precision-T study evaluating Orca-T, an investigational allogeneic T-cell immunotherapy for various blood cancers including AML, ALL, and high-risk MDS.
• The innovative therapy utilizes highly purified regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from matched donors' peripheral blood, representing a potential advancement in blood cancer treatment.
• The study's findings position Orca-T as a promising late-stage candidate in the cellular therapy landscape, potentially offering new options for patients with difficult-to-treat hematologic malignancies.
Nutrition's Critical Role in Cancer Care: From Prevention to Survivorship
• Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.
• Recent research highlights the link between obesity and processed foods with increased cancer risk, with many oncologists now recommending Mediterranean-style diets rich in colorful fruits and vegetables.
• Multidisciplinary care teams including dietitians are essential for managing treatment-related symptoms and developing sustainable, evidence-based nutrition plans that improve long-term outcomes.
Novel Chemo-Immunotherapy Approach Shows Promise for Advanced HPV-Negative Head and Neck Cancer
• A Phase 2 clinical trial at UChicago Medicine demonstrated that combining nivolumab immunotherapy with chemotherapy led to tumor shrinkage in 53% of advanced HPV-negative head and neck cancer patients.
• The innovative treatment approach, which included response-adaptive chemo-radiation therapy, showed improved survival outcomes and reduced toxic side effects, particularly in patients who responded well to initial treatment.
• Higher PD-L1 expression levels were associated with better treatment responses, suggesting its potential as a biomarker for predicting treatment outcomes in this patient population.
Sofinnova Partners Secures €1.2 Billion to Fuel Next Wave of Biotech Innovation
• European venture capital firm Sofinnova Partners has raised €1.2 billion ($1.3 billion) in fresh funds to invest in life sciences and healthcare companies, with plans to support 50-60 new ventures.
• Since 2022, Sofinnova has backed 21 biotech companies across various therapeutic modalities, including gene therapy company Chroma Medicine and AstraZeneca-acquired firms CinCor Pharma and Amolyt Pharma.
• The fundraise comes amid a shifting venture capital landscape, where total biotech funds have decreased from 137 in 2021 to 38 in 2024, with investors increasingly prioritizing companies with validated clinical data and clear commercialization pathways.
Global Clinical Trials for Myelodysplastic Syndrome Show Significant Industry Investment in 2025
• A comprehensive review of global Myelodysplastic Syndrome clinical trials reveals extensive research activity across G7 and E7 countries, with major pharmaceutical companies leading development efforts.
• The analysis highlights significant participation from industry leaders including Bristol-Myers Squibb, Novartis, and Sanofi, demonstrating strong commercial interest in MDS therapeutics.
• The report indicates evolving clinical trial landscapes across multiple regions, with detailed tracking of trial phases, enrollment trends, and success rates over the past five years.
Early Leqembi Patient's Journey Highlights Promise and Limitations of New Alzheimer's Treatment
• One of the first U.S. patients to receive Leqembi (lecanemab) in 2020, Sue Bell's four-year treatment journey provides insights into the drug's real-world impact on Alzheimer's progression.
• While Leqembi successfully clears beta-amyloid plaques and can slow disease progression, the $25,000-per-year treatment shows varying effectiveness among patients and does not restore lost cognitive function.
• After four years of twice-monthly infusions, Sue Bell discontinued treatment as her condition progressed beyond the early stage where Leqembi provides optimal benefit.
Novel Approaches Transform Lymphoma Treatment Landscape: From Genomic Profiling to Liquid Biopsies
• Dr. David Russler-Germain highlights revolutionary shifts in lymphoma treatment, from traditional chemotherapy to targeted therapies including BTK inhibitors, CAR-T cells, and bispecific antibodies.
• Groundbreaking research in follicular lymphoma genomic profiling reveals crucial mutations, advancing understanding of disease mechanisms and treatment approaches.
• Circulating tumor DNA emerges as a promising non-invasive biomarker for real-time monitoring of lymphoma progression and treatment response.
Landmark Prevention Trial Launches to Stop Alzheimer's Before Symptoms Begin in Young Adults
• WashU Medicine initiates groundbreaking international trial testing Eli Lilly's remternetug in young adults as young as 18, targeting Alzheimer's prevention up to 25 years before expected symptom onset.
• The Primary Prevention Trial will enroll 240 participants from families with genetic mutations, focusing on removing or preventing amyloid beta plaques before cognitive symptoms develop.
• The $130 million study represents a collaborative effort between academic institutions, pharmaceutical industry, and foundations, with support from NIH, Alzheimer's Association, and private donors.
GLP-1 Agonists Linked to Reduced Risk of 42 Health Conditions in Large Study
• A large observational study of nearly 2 million patients found that GLP-1 receptor agonists (GLP-1RAs) are associated with a reduced risk of 42 health conditions.
• The study, which included 215,000 GLP-1RA users, showed benefits beyond glucose control and weight loss, including neurological and respiratory conditions.
• While GLP-1RAs demonstrated broad benefits, the study also identified increased risks for certain conditions like kidney stones and low blood pressure.
• Researchers emphasize the need for further studies to confirm these findings and understand the long-term effects of GLP-1RA therapy.
FDA Approves Monthly IV Maintenance Dosing for Leqembi, Eases Treatment Burden for Alzheimer's Patients
• The FDA has approved a monthly intravenous (IV) maintenance dose for Leqembi, offering a more convenient treatment schedule for early Alzheimer's disease.
• Patients completing the initial 18-month biweekly IV treatment can transition to monthly dosing, potentially improving long-term adherence and quality of life.
• Approval is based on data modeling showing sustained clinical and biomarker benefits with monthly dosing, addressing the continuous neurotoxic processes of Alzheimer's.
• Leqembi, developed by Eisai and Biogen, is now approved in multiple countries, offering a significant advancement in managing early Alzheimer's disease.
FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management
• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.
• Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids.
• Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations.
• Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.
EU Review of Lecanemab for Early Alzheimer's Faces Further Scrutiny
• The European Commission has requested further review of lecanemab's safety data by the CHMP after its initial positive opinion in November 2024.
• The CHMP will assess new safety information and the clarity of risk minimization measures at its February 2025 meeting.
• Eisai and Biogen affirm that post-launch safety data from the U.S., Japan, and other countries align with approved labels, with no new safety signals detected.
• Both companies are committed to addressing the EC's requests and delivering lecanemab to EU patients with early Alzheimer's as quickly as possible.
Personalized Vaccine Shows Promise in Triple-Negative Breast Cancer
• A novel personalized vaccine demonstrates potential in treating aggressive triple-negative breast cancer, offering a new therapeutic avenue.
• In a small clinical trial, 16 of 18 patients remained cancer-free three years post-vaccination, surpassing historical data for surgery alone.
• The vaccine is designed to train the immune system to target unique genetic mutations in individual patients' tumor cells.
• Larger randomized controlled trials are underway to further evaluate the vaccine's efficacy compared to the standard of care.
PrecivityAD2 Blood Test Enhances Alzheimer's Diagnosis and Treatment Decisions
• The PrecivityAD2 blood test significantly improves diagnostic confidence for Alzheimer's disease, increasing it from 50-60% to over 90% among clinicians.
• Clinical integration of the PrecivityAD2 test leads to a 35% increase in prescriptions for Alzheimer's disease medications for patients with positive results.
• The test demonstrates high concordance (99%) with intended clinical use and maintains a diagnostic accuracy of 90% when compared to cerebrospinal fluid analysis.
• PrecivityAD2's Amyloid Probability Score 2 (APS2) effectively differentiates Alzheimer's disease pathology, aiding in more accurate diagnosis and treatment planning.
IMUNON's IMNN-001 Receives FDA Agreement on Manufacturing for Phase 3 Ovarian Cancer Trial
• IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer.
• The FDA has accepted IMUNON's potency assay for measuring interferon-gamma (IFN-γ) levels, crucial for both Phase 3 trials and potential commercial use.
• IMUNON's in-house manufacturing facility in Huntsville, Alabama, will produce IMNN-001, ensuring cost-efficient production and quality control.
• The company remains on track to initiate the 500-patient Phase 3 pivotal trial of IMNN-001 in the first quarter of 2025.
AMX0035 Shows Sustained Improvements in Wolfram Syndrome Patients in Phase 2 Trial
• Amylyx Pharmaceuticals' AMX0035 demonstrated sustained improvements in pancreatic function in adults with Wolfram syndrome in a Phase 2 trial.
• The HELIOS trial showed improvements in C-peptide response, glycemic control, and visual acuity over 24 weeks of treatment with AMX0035.
• Longer-term data up to 48 weeks indicated sustained improvements in C-peptide and HbA1c levels, suggesting potential for disease trajectory modification.
• AMX0035 was generally well-tolerated, with a safety profile consistent with prior data, supporting further investigation in a Phase 3 program.
© Copyright 2025. All Rights Reserved by MedPath